Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study

Blood

Volumn 113, Issue 19, 2009, Pages 4497-4504

  Baccarani, Michele ^a   Rosti, Gianantonio ^a   Castagnetti, Fausto ^a   Haznedaroglu, Ibrahim ^b   Porkka, Kimmo ^c   Abruzzese, Elisabetta ^d   Alimena, Giuliana ^e   Ehrencrona, Hans ^f   Hjorth Hansen, Henrik ^g   Kairisto, Veli ^h   Levato, Luciano ⁱ   Martinelli, Giovanni ^a   Nagler, Arnon ^j   Nielsen, Johan Lanng ^k   Ozbek, Ugur ^l   Palandri, Francesca ^a   Palmieri, Fausto ^m   Pane, Fabrizio ⁿ   Rege Cambrin, Giovanna ^o   Russo, Domenico ^p   Specchia, Giorgina ^q   Testoni, Nicoletta ^a   Weiss Bjerrum, Ole ^r   Saglio, Giuseppe ^o   Simonsson, Bengt ^f   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HACETTEPE UNIVERSITY   (Turkey)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h TURKU UNIVERSITY HOSPITAL   (Finland)

ⁱ Regional Hospital   (Italy)

^j SHEBA MEDICAL CENTER   (Israel)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l ISTANBUL UNIVERSITY   (Turkey)

^m General Hospital   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o UNIVERSITY OF TURIN   (Italy)

^p UNIVERSITY OF BRESCIA   (Italy)

^q UNIVERSITY OF BARI   (Italy)

^r Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC DIARRHEA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADOLESCENT; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; EUROPE; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66549108340     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-191254     Document Type: Article

References (53)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037. (Pubitemid 32267972)
2. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. (Pubitemid 34815868)
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
4. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937. (Pubitemid 34525471)
5. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539. (Pubitemid 34534519)
6. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820. (Pubitemid 44394987)
7. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003;9:2092-2097. (Pubitemid 36687630)
8. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003; 101:473-475. (Pubitemid 36077567)
9. Cortes J, Giles F, O'Brien S, et al. Result of highdose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003; 102:83-86. (Pubitemid 36759639)
10. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103:2873-12848 (Pubitemid 38451654)
11. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
12. Rosti G, Trabacchi E, Bassi S, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica. 2003;88:256-259
13. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-1432. (Pubitemid 37211057)
14. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37. (Pubitemid 43990609)
15. Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood. 1998;91:3357-3365.
16. Primo D, Tabernero A, Rasillo A, et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia. 2003;17:1124-1129. (Pubitemid 36722243)
17. Raanani P, Ben-Bassat I, Gan S, et al. Assessment of the response to imatinib in chronic myeloid leukemia patients: comparison between the FISH, multiplex and RT-PCR methods. Eur J Haematol. 2004;73:243-250. (Pubitemid 39278850)
18. Marzocchi G, Luatti S, Amabile M, et al. A prospective study in Ph+ CML patients: FISH is effective as conventional cytogenetics for defi- nition of cytogenetic response to imatinib: correlation with molecular response (a GIMEMA WP analysis). Haematologica. 2007;92(suppl 1):50.
19. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20:1925-1930. (Pubitemid 44614879)
20. Müller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RTPCR. Haematologica. 2007;92:970-973. (Pubitemid 350144244)
21. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330-3338.
22. Müller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22:96-102.
23. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20:859-866.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
25. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935-942. (Pubitemid 41103606)
26. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol. 2005;60:35-44. (Pubitemid 40942779)
27. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of Imatinib Mesylate in healthy volunteers. Drug Metab Dispos. 2005;33: 1503-1512. (Pubitemid 41323999)
28. Peng B, Lloyd P, Shran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44: 879-894.
29. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
30. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose Imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499. (Pubitemid 46572540)
31. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein- mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401-408. (Pubitemid 38425851)
32. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104: 3739-3745. (Pubitemid 39564452)
33. White DL, Saunders VA, Dang P, et al. OCT-1- mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006; 108:697-704. (Pubitemid 44061372)
34. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064-4072. (Pubitemid 350248463)
35. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res. 2008;14:3141-3148.
36. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard- dose imatinib in chronic myeloid leukemia. Blood. 2008;112:2024-2027.
37. Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003; 101:4611-4614. (Pubitemid 36857835)
38. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283. (Pubitemid 36759665)
39. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23:4100-4109. (Pubitemid 46211315)
40. Martinelli G, Soverini S, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005;19:1872-1879. (Pubitemid 41553994)
41. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006; 20:1767-1773. (Pubitemid 44574988)
42. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112:3965-3973.
43. Rosti G, Castagnetti F, Amabile M, et al. Imatinib high dose (800 mg) in intermediate Sokal risk CML patients in chronic phase: results of a Phase II trial of the GIMEMA CML WP [abstract]. Haematologica. 2007;92(suppl):205. Abstract 0550.
44. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
45. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837-845.
46. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-3363.
47. Saldanha J, Silvy M, Beaufils N, et al. Characterization of a reference material for BCR-ABL (MBCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia. 2007;21: 1481-1487. (Pubitemid 46965290)
48. Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S; Association for Molecular Pathology Hematopathology Subdivision. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn. 2007;9:421-430.
49. Baccarani M, Haznedaroglu I, Porkka K, et al. A prospective randomized study of imatinib 400 mg vs 800 mg as a frontline therapy in Sokal high risk (HR) Ph pos chronic myeloid leukemia [abstract]. Haematologica. 2008;93(suppl):161. Abstract 0405.
50. Andreas AP, Wolf DW, Fong DF, et al. High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (MCR, CCR) - results from the first planned interim analysis of a multicenter, randomised, 2 arm phase III study comparing imatinib standard dose (400 mg/day) with imatinib high dose [abstract]. Haematologica. 2008; 93(suppl):162. Abstract 0406.
51. Cortes JG, Baccarani M, Guilhot F, et al. First report of the TOPS study: a randomized phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints [abstract]. Haematologica. 2008;93(suppl):160. Abstract 0402.
52. Hehlmann R, Saussele S, Lauseker M, et al. Randomized comparison of Imatinib 400 mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 mg: optimized treatment and survival. Designed first interim analysis of the German CML Study IV [abstract]. Blood. 2008;112:Abstract 184.
53. Guilhot F, Mahon F-X, Guilhot J, et al. Randomized comparison of Imatinib versus Imatinib combination therapies in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML Group (FI LMC) [abstract]. Blood. 2008;112:Abstract 183.